Discovery of furo[2,3-b]isoquinoline derivatives as novel Pks13 inhibitors with reduced hERG inhibition
- 26 January 2026
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 134, 130561
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (22307024)
- National Natural Science Foundation of China (32394010)
- Basic and Applied Basic Research Foundation of Guangdong Province (2023A1515011885)
This publication has 23 references indexed in Scilit:
- Identification and Optimization of Novel Inhibitors of the Polyketide Synthase 13 Thioesterase Domain with Antitubercular ActivityJournal of Medicinal Chemistry, 2023
- Targeting polyketide synthase 13 for the treatment of tuberculosisEuropean Journal of Medicinal Chemistry, 2023
- Structure-Based Optimization of Coumestan Derivatives as Polyketide Synthase 13-Thioesterase(Pks13-TE) Inhibitors with Improved hERG Profiles for Mycobacterium tuberculosis TreatmentJournal of Medicinal Chemistry, 2022
- hERG toxicity assessment: Useful guidelines for drug designEuropean Journal of Medicinal Chemistry, 2020
- Phenolic Naphthoxazines as Curing Promoters for BenzoxazinesMacromolecules, 2018
- Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13Cell, 2017
- Development of Safe Drugs: The hERG ChallengeMedicinal Research Reviews, 2017
- Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosisInfection, Genetics and Evolution, 2016
- Drugs, hERG and sudden deathCell Calcium, 2004
- Phase-Vanishing Reactions that Use Fluorous Media as a Phase Screen. Facile, Controlled Bromination of Alkenes by Dibromine and Dealkylation of Aromatic Ethers by Boron TribromideJournal of the American Chemical Society, 2002